Rheumnow Podcast

Join RheumNow faculty to recap the best and most interesting data presented at ACR22 in the area of SLE.  Sunday - SLE Panelists: Drs. Kathryn Dao, Bella Mehta, Yuzaiful Yusof, Eric Dein, Michael Putman, Sheila Reyes, Janet Pope

ACR 2022 Daily Recap for Sunday, November 13th.

AI Future of Sacroiliitis Assessment Dr. Rachel Tate speaks with Dr. Fabian Proft about Abstract 0383 at ACR22 Convergence. Can I stop Methotrexate in RA? Dr. Janet Pope and Dr. Charis Meng discuss Abstract 0916 at ACR22 Convergence.  Abstract 0916: Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis CAR-T Therapies in Antiphospholipid Antibody Syndrome Dr. Michael Putman and Dr.  Maximilian Konig discuss abstract 1677 at ACR22 Convergence.  Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells Copays Reduce Adherence to SLE Medications Dr. Michael Putman reports on abstract 1115 at ACR22 Convergence in Philadelphia, PA. Copays Reduce Adherence to SLE Medications Dr. Michael Putman reports on abstract 1115 at ACR22 Convergence in Philadelphia, PA. Does Race play a role in Mycophenolate Response in Scleroderma? Dr. Eric Dein speaks with Dr. Lauren Smith about abstract 0521 at ACR22 Convergence in Philadelphia, PA. Abstract 0521: Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis Fertility issues in SpA Dr. Sheila Reyes speaks with Dr. Sabrina Hamroun about abstract 1673 at ACR22 Convergence.  Abstract 1673: Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort Opioid use in PsA and SpA Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence PsA and SPA: Cyclers, Switchers, Who is the Winner? Dr. Aurelie Najm discusses abstracts 1499 and 1600 at ACR22 Convergence in Philadelphia, PA. Remibrutinib in Sjogren's Syndrome Dr. Michael Putman reports on abstract 1113 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study      

Advancing Telehealth in Rheumatology Dr. Cush at ACR22 Convergence in Philadelphia, PA. Artificial Intelligence in Detecting Sacroiliitis Dr. Akhil Sood discusses Abstract 0383 at ACR22 Convergence. Abstract 0383: Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA COVID Highlights Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders Impact of COVID 19 on Pregnancies in Women with RMD Dr. Cassy Sims discusses abstract 0950 at ACR22 Convergence. Abstract 0950: Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry Photovoice: A New Visual Research Method in Lupus Dr. Bella Mehta talks with Dr. Candace Feldman about Abstract 1099 at ACR22 Convergence. Abstract 1099: Empowering Patients with Lupus Through Their Photographs: Application of the Photovoice Method to Understand Social Determinants of Health PreRA to Treat or Not! Dr. Janet Pope discusses the Great Debate at ACR22 Convergence in Philadelphia.  Prescribing Methotrexate in Post-Roe Era   Dr. Cassy Sims reports live from ACR22 Convergence in Philadelphia, PA. L09: Impact on Access to Methotrexate in the Post-Roe Era To Switch or Not: Biosimilars in Inflammatory Arthritis Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.   Women vs. Men: Response to Treatment in Seronegative Arthritis Dr. Janet Pope discusses abstracts 1614 and 1601 at ACR22 Convergence in Philadelphia, PA        

Advancing Telehealth in Rheumatology Dr. Cush at ACR22 Convergence in Philadelphia, PA. Artificial Intelligence in Detecting Sacroiliitis Dr. Akhil Sood discusses Abstract 0383 at ACR22 Convergence. Abstract 0383: Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA COVID HighlightsDr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders Impact of COVID 19 on Pregnancies in Women with RMD Dr. Cassy Sims discusses abstract 0950 at ACR22 Convergence. Abstract 0950: Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry Photovoice: A New Visual Research Method in Lupus Dr. Bella Mehta talks with Dr. Candace Feldman about Abstract 1099 at ACR22 Convergence. Abstract 1099: Empowering Patients with Lupus Through Their Photographs: Application of the Photovoice Method to Understand Social Determinants of Health Prescribing Methotrexate in Post-Roe Era Dr. Cassy Sims reports live from ACR22 Convergence in Philadelphia, PA.3 L09: Impact on Access to Methotrexate in the Post-Roe Era Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar Dr. Julian Segan discusses Abstract 1425 at ACR22 Convergence. Abstract 1425: Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases          

Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.  Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome JAK vs TNF inhibitor Infections in RA Dr. David Liew discusses abstract 0302 at ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting. The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.  Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK) What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Dr Chao discusses Abstract 1510 at ACR22 Convergence. Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries    

2023 RWCS Meeting Dr. Arthur Kavanaugh invites you to join him for the 2023 RWCS meeting in February 2023. Dr David Liew JAK inhibitor VS TNF inhibitor, Infections in East Asian Patients. Abstract 302 Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan talks with Dr.  Nelly Ziade at ACR22 Convergence in Philadelphia, PA. Abstracts 1512: What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain Abstract 1517: Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain New Treatments for SLE? Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA.  Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

ACR2022 Daily Recap for Saturday, November 12th.

Breakthrough COVID infection in SLE during Omicron era Dr. Yusof talks with Dr. Amit Saxena about abstract 2081 at ACR22 Convergence. Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Olga Petryna discusses abstract 0377 presented at ACR22 Convergence. Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies

A Year in Review Dr. Jack Cush, Philadelphia Differences in Clinical Presentation and Outcomes of Early vs Late Onset PsA Dr. Olga Petryna, New York Abstract 0377 mTORC1 as a Driver of Inflammation in sJIA Connecting Pathogens of sJIA and MAS Dr. Olga Petryna, New York Abstract 0004 Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims discusses abstract 0199 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0199: Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis The CONSUL Trial Dr. Sheila Reyes, The Phillipines Abstract 0526